Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped

Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

Moderna Cancer Trial Success Is a Shot in the Arm for Trump

An mRNA success is something of a vindication for Trump (and the Biden years), but an embarrassment for RFK Jr.

Moderna co-founder is a billionaire once again at $1.7 billion—he once turned down 20 high-paying job offers to have more of an impact on the world

Billionaire biotech pioneer Robert Langer advises workers to do what makes them happy over money and job security: “If you give up too easily, that's not good.”

Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock soared.

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

Novel Cancer Vaccine Prevents Melanoma From Returning in First for mRNA

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
Blockonomi

Moderna, Inc. (MRNA) Stock: Jefferies Sees $54B Peak Sales for Cancer Therapy

Moderna shares fell sharply despite positive melanoma trial results as Jefferies modeled $54 billion in peak sales for its growing cancer therapy pipeline.

Moderna is up 350% since our recommendation. Here’s what to do next.

Moderna’s breakthrough highlights a broader transformation, as AI accelerates the clinical development of therapies at a pace that would have seemed unimaginable a few years ago.